Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in
improving overall survival of several malignancies associated with poor outcomes; however …
improving overall survival of several malignancies associated with poor outcomes; however …
Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
R Malmberg, M Zietse, DW Dumoulin… - The Lancet …, 2022 - thelancet.com
Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable
responses to many patients with solid and haematological cancers. The high prices and …
responses to many patients with solid and haematological cancers. The high prices and …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …
melanoma have been significantly revised over the past few years in response to emerging …
[HTML][HTML] Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang… - Annals of …, 2017 - Elsevier
Background Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the
standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell …
standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell …
Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer
Y Feng, X Wang, G Bajaj, S Agrawal, A Bello… - Clinical Cancer …, 2017 - AACR
Purpose: Nivolumab is a fully human IgG4 monoclonal antiprogrammed death-1 antibody
with demonstrated efficacy, including durable responses and prolonged survival, in patients …
with demonstrated efficacy, including durable responses and prolonged survival, in patients …
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
DP Hurkmans, EA Basak, T van Dijk… - … for immunotherapy of …, 2019 - Springer
Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For
patients with non-small cell lung cancer (NSCLC), a potential exposure-response …
patients with non-small cell lung cancer (NSCLC), a potential exposure-response …
[HTML][HTML] Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies
A Desnoyer, S Broutin, J Delahousse, C Maritaz… - European Journal of …, 2020 - Elsevier
Immune checkpoint inhibitors are monoclonal antibodies (mAbs) directed against negative
immunologic regulators that are used to restore the immune response against cancer …
immunologic regulators that are used to restore the immune response against cancer …
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and …
F Petrelli, R Ardito, B Merelli, V Lonati… - Melanoma …, 2019 - journals.lww.com
Levels of serum lactate dehydrogenase (LDH) are a recognized prognostic factor in
malignant melanoma (MM). It is relevant to confirm its prognostic role in patients treated with …
malignant melanoma (MM). It is relevant to confirm its prognostic role in patients treated with …
[HTML][HTML] Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
X Zhao, J Shen, V Ivaturi, M Gopalakrishnan, Y Feng… - Annals of …, 2020 - Elsevier
Background Nivolumab 480 mg every 4 weeks (Q4W) is approved in the European Union,
United States, and several other markets across multiple tumor types. Its approval was …
United States, and several other markets across multiple tumor types. Its approval was …
Characterizing exposure–response relationship for therapeutic monoclonal antibodies in immuno‐oncology and beyond: challenges, perspectives, and prospects
HI Dai, Y Vugmeyster, N Mangal - Clinical Pharmacology & …, 2020 - Wiley Online Library
Recent data from immuno‐oncology clinical studies have shown the exposure–response (E–
R) relationship for therapeutic monoclonal antibodies (mAbs) was often confounded by …
R) relationship for therapeutic monoclonal antibodies (mAbs) was often confounded by …